Alcanza Clinical Research has acquired Tampa Bay Medical Research, an independent clinical research center with nearly four decades of operational history. The acquisition adds TBMR's established facilities and expertise to Alcanza's growing national network of research sites.
Tampa Bay Medical Research, founded in 1984, has completed more than 600 clinical trials across broad therapeutic areas for over 70 pharmaceutical and medical device sponsors. With facilities totaling over 5000 square feet in Clearwater and Largo, TBMR has built a reputation for operational excellence through its multidisciplinary team of Principal Investigators and certified clinical research coordinators.
"Partnering with high quality clinical research businesses and operators remains a top priority for us," said Carlos Orantes, CEO at Alcanza Clinical Research. The acquisition represents a strategic move to expand Alcanza's national footprint while preserving the local expertise and personalized care that TBMR participants and sponsors have relied upon for decades.
TBMR's leadership includes CEO and Medical Director Sureka Bollepalli, MD, a board-certified endocrinologist with over 20 years of experience conducting NIH and industry-sponsored trials. "We are excited to begin this next chapter with Alcanza Clinical Research," said Dr. Bollepalli. "This partnership strengthens our ability to support patients, deepen community engagement, and expand access to high-quality clinical research—allowing us to advance care and improve lives together."
The integration combines TBMR's operational excellence and community presence with Alcanza's scalable infrastructure and strategic partnerships. This combination positions the organization to accelerate clinical research and broaden access to innovative treatment opportunities for patients throughout the Tampa Bay region and beyond.
Alcanza Clinical Research operates as an integrated network of research facilities focused on bringing clinical trial opportunities involving life-changing treatments and vaccines to all patients, with particular emphasis on under-represented communities. The network includes 25 dedicated research units and additional integrated specialty clinic sites strategically located throughout multiple U.S. regions and Puerto Rico. More information about Alcanza's operations can be found at https://alcanzaclinical.com.
For business and technology leaders in healthcare, this acquisition signals continued consolidation in the clinical research sector, where scale and specialized expertise increasingly determine competitive advantage. The move enables Alcanza to leverage TBMR's established community relationships and nearly four-decade track record while providing TBMR with access to broader resources and infrastructure. This type of strategic integration addresses critical industry challenges around patient recruitment diversity, operational efficiency, and geographic coverage—factors that directly impact the speed and quality of medical innovation reaching patients.
